H.C. Wainwright Affirms MannKind Corp (MNKD)'s 'Buy' Rating Buoyed by Product Pipeline

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed coverage of the stock with a ‘Buy’ rating and a $9 price target. The bullish stance is based on the company’s demonstrated strong growth of 32.5% over the last 12 months.

The research firm expects Tyvaso DPI to be one of the key factors driving MannKind’s valuation in the near future. Nevertheless, it maintains a cautious outlook on the Afreezza product line, expected to generate $127 million in sales by 2030.

H.C. Wainwright’s Buy rating and $9 price target are also based on expectations that MannKind’s product pipeline, including MNKD-101 and MNKD-201, will achieve 40% and 30% probability of success, respectively.

MannKind Corporation (NASDAQ:MNKD) develops and commercializes inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases. Its primary product is Afrezza, an inhaled ultra-rapid-acting insulin for diabetes.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 9 Best AI Stocks to Buy According to Billionaire Stanley Druckenmiller and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty.

Disclosure: None. This article is originally published at Insider Monkey.